DDrare: Database of Drug Development for Rare Diseases

206. 脆弱X症候群
［臨床試験数：98，薬物数：73（DrugBank：27），標的遺伝子数：46，標的パスウェイ数：57］

Searched query = "Fragile X syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 11C-flumazenil; 18F-FTC-146; ACIDUM ASCORBICUM D6; AF056; AFQ056; AZD7325; AZD7325 (High-Dose); AZD7325 (Low-Dose); Acamprosate; Acetate; Acidum ascorbicum; Alpha-tocopherol; Ampalex; Arbaclofen; Aripiprazole; Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E); Ascorbic acid; BPN14770; CBD; CCD 1042, MD 9150000, Mepalon 1042, SPT316; CX516; CX516 (Ampalex®); Donepezil; EGCG; EGCG FontUp; Flumazenil; Fluoxetin; GANAXOLONE; Gaboxadol; Ganaxolone; Lovastatin; Lovastatin, then Minocycline/Lovastatin; MG01CI extended-release tablet; MGlu5 antagonist; Mavoglurant; Metformin; Methylphenidate; Methylphenidate, fluoxetin, risperidone; Minocycline; Minocycline hydrochloride; Minocycline, then Minocycline/Lovastatin; NNZ-2566; NPL-2009; OV101; OV101 (gaboxadol); Other: Biological samples; Other: Cognitive training; Other: Language Intervention; Other: MRI; Oxytocin; Oxytocin 24IU; Oxytocin 48IU; RO4917523; RO4917523 0.5 mg; RO4917523 1.5 mg; Riluzole; Risperidone; Ro 491-7523/F18; Ro 491-7523/F19; STX107; STX209; Sertraline; Sugar pill; TOCOPHERYL ACETATE; Tocopherol; Tocopheryl acetate; Vitamin C; Vitamin C 10mg/Kg Vitamin E 10 mg/Kg; Vitamin E; ZYN002 - CBD Transdermal Gel; [18F]FPEB; [18F]FPEB PET imaging; [18F]flumazenil

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03802799 (ClinicalTrials.gov)	November 9, 2018	26/12/2018	Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS	An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome - CONNECT-FX Open Label Extension (OLE)	Fragile X Syndrome	Drug: ZYN002 - CBD Transdermal Gel	Zynerba Pharmaceuticals, Inc.	NULL	Recruiting	3 Years	18 Years	All	300	Phase 2;Phase 3	United States;Australia;New Zealand
2	NCT03614663 (ClinicalTrials.gov)	June 12, 2018	10/7/2018	Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)	A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome	Fragile X Syndrome	Drug: ZYN002 - CBD Transdermal Gel;Other: Placebo Transdermal Gel	Zynerba Pharmaceuticals, Inc.	NULL	Completed	3 Years	17 Years	All	212	Phase 2;Phase 3	United States;Australia;New Zealand

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03802799
(ClinicalTrials.gov)

November 9, 2018

26/12/2018

Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS

An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome - CONNECT-FX Open Label Extension (OLE)

Fragile X Syndrome

Drug: ZYN002 - CBD Transdermal Gel

Zynerba Pharmaceuticals, Inc.

NULL

Recruiting

3 Years

18 Years

All

300

Phase 2;Phase 3

United States;Australia;New Zealand

NCT03614663
(ClinicalTrials.gov)

June 12, 2018

10/7/2018

Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)

A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome

Fragile X Syndrome

Drug: ZYN002 - CBD Transdermal Gel;Other: Placebo Transdermal Gel

Zynerba Pharmaceuticals, Inc.

NULL

Completed

3 Years

17 Years

All

212

Phase 2;Phase 3

United States;Australia;New Zealand